TO PLACE YOURORDER CONTACT:
(kit for the preparation of indium In-111 pentetreotide)
DETECTUniquely targeted for identification of neuroendocrine tumors bearing somatostatin receptors.1
LOCALIZEHighly sensitive for a variety of primary neuroendocrine tumors and metastases.2,3
INFORMProvides valuable clinical information to support the diagnosis and selection of a treatment plan.4,5
INDICATIONS AND USAGE
Octreoscan Kit for the Preparation of Indium In-111 Pentetreotide is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
IMPORTANT RISK INFORMATION WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
1 Octreoscan™ imaging agent package insert.2 Krenning E, Kwekkeboom D, Pauwels S, Kvols L, Reubi J. Somatostatin Receptor Scintigraphy. In: Freeman L, ed. Nucl Med Annual. Raven Press; 1995: 1-50.3 Modlin I, Kidd M, Latich I, Zikusoka M, Shapiro M. Current Status of Gastrointestinal Carcinoids. Gastroenterology. 2005; 128: 1717-1751.4 Rufini M, Calcagni M, Baum R. Imaging of Neuroendocrine Tumors. Sem Nucl Med. 2006; 36: 228-247.5 Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997; 38: 853-858.
Mallinckrodt, the “M” brand mark, and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2015 Mallinckrodt.
Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.